The Numbers That Should Make You Pause
Six out of eight children. That’s the remission rate reported in 2025 from Great Ormond Street Hospital Gene Therapy Research, and I need to be careful here because preliminary data can be misleading. But also, we need to sit with what this actually means. These were kids with T-cell acute lymphoblastic leukemia, a cancer that once meant almost certain death. A year after treatment, most of them were still cancer-free. The quiet part that most coverage missed? This wasn’t just a win for gene therapy. It was a demonstration that a fundamentally different approach to editing DNA is starting to work in human patients.
When I first read the details, I found myself thinking about scale in a way I haven’t since learning about the difference between mitochondria and their host cells. Base editing operates on a scale so granular, so absurdly precise, that it almost defies intuition. We’re talking about changing individual letters in the genetic code without breaking the DNA strand itself. That sounds like a technical distinction until you realize it might be the difference between a therapy that works and one that creates new problems while solving old ones.
The Problem With Breaking DNA (And Why Base Editors Don’t)
Standard CRISPR-Cas9, the technology that won the Nobel Prize and rightfully so, works like molecular scissors. Find the target DNA sequence, cut both strands cleanly, and let the cell’s repair machinery fill in the gap with your desired edit. The system is elegant. It’s powerful. And here’s the part that keeps molecular biologists awake at night: sometimes the cell’s repair machinery gets confused. Sometimes it makes large chromosomal deletions. Sometimes it rearranges big chunks of DNA in ways that weren’t on the agenda.
Base editors approach the problem differently. Instead of cutting the DNA strand, they chemically convert one letter of the genetic code into another, like changing an A to a G without severing the backbone of the molecule. Think of it as editing a sentence by replacing individual letters rather than cutting the page and hoping the glue gun cooperates. The practical result is that base editing dramatically reduces the risk of large-scale chromosomal damage and off-target rearrangements that could cause new disease.
A 2025 meta-analysis published in The Lancet quantified this advantage: base editing reduces detectable off-target edits by roughly tenfold compared to standard CRISPR in human blood-forming stem cells. Tenfold. That’s not a marginal improvement. That’s a category shift in safety profile. And safety, especially when you’re treating children, isn’t just a nice-to-have feature.
Four Edits, One Impossible-Seeming Therapy
The treatment Waseem Qasim’s team at UCL developed isn’t using base editing to fix one thing. It’s using it to edit donor T-cells at four different locations in the genome, creating a cell that is simultaneously invisible to the patient’s immune system, capable of recognizing and attacking leukemia cells, resistant to chemotherapy, and incapable of attacking healthy tissue. When I try to hold all four of those properties in my head at once, I get the same feeling I get trying to visualize a four-dimensional hypercube.
The elegance here runs deeper than just the number of edits. The therapy uses cells from a healthy donor rather than cells from the patient. This matters enormously, because it means you could theoretically manufacture these cells once and use them across many patients. You’re not waiting weeks for each child’s immune cells to be extracted, edited, and expanded. You have off-the-shelf engineered soldiers ready to deploy.
And yet, those four edits work in concert. Remove the markers that the patient’s immune system recognizes, and the donor cells persist. Edit in a CAR receptor, and they hunt cancer. Confer resistance to alemtuzumab, the chemotherapy drug used to prepare the patient’s body for the new cells, and they survive treatment. Block the signals that cause graft-versus-host disease, and they don’t attack the body they’re supposed to save. This is multivariate molecular engineering at a scale that feels genuinely science-fictive when you stop and think about it.
The Horizon Beyond Leukemia
The Great Ormond Street results are thrilling partly because they’re happening now, with kids who needed help now, not in some theoretical future. But they’re also thrilling because they’re proof of concept for something much larger. Beam Therapeutics Clinical Pipeline recently reported that their base editing therapy for sickle cell disease, BEAM-101, induced elevated fetal hemoglobin in every patient in Phase 1/2 trials, with levels exceeding 40 percent in all cases. Sickle cell disease is fundamentally a single-letter problem: a mistake in the beta-globin gene that causes red blood cells to crescent and sickle. Base editing is the tool that can fix that single letter.
That’s the real revolution happening here. Not one cure. Multiple diseases where base editing addresses the root cause at a molecular level. And the fact that this approach produces fewer off-target edits, a tenfold reduction in detectable collateral damage, suggests we might be able to edit genes in ways that felt too risky with previous tools.
Why This Matters Beyond the Lab
I think about the parents of those eight children in London and imagine the weight of watching your child receive a therapy that barely existed as a concept five years ago. I think about the probability that if you’re reading this, there’s someone in your life who might benefit from base editing in the next decade. And I think about how easy it is for medical breakthroughs to become noise, just another headline about CRISPR, when the actual molecular events happening are borderline incomprehensible in their precision.
This is the moment to pay attention. Not because I’m certain base editing will solve everything, but because we’re watching the transition from promise to practice. A technology that reduces certain kinds of risk, works on multiple diseases, and can be engineered at a complexity that would have seemed impossible not long ago. The children who went into remission aren’t waiting for perfect certainty. They’re living in the present tense of this breakthrough.
What aspects of this technology puzzle you most? What questions would you want answered before considering base editing for a treatable disease? I’d genuinely like to know what keeps other people awake at 3am reading about molecular biology.